Iovance Q2 2026 Earnings: Amtagvi Drives 66% Revenue Growth and a Narrower Loss

Iovance Biotherapeutics (NASDAQ: IOVA) reported second-quarter 2026 revenue of $99.3 million, up 66% from $60.0 million a year earlier, while basic and diluted EPS was -$0.11 versus -$0.33. U.S. Amtagvi revenue of approximately $91 million drove most of the sales, while a 56% gross margin and lower R&D spending helped narrow the net loss to $47.3 million from $111.7 million. The quarter ended June 30, 2026, and the results were released on August 6.

Core earnings data

Revenue growth was accompanied by substantial improvement in loss metrics. The comparison below covers the three months ended June 30, with calculated changes shown on an approximate basis.

The prior-year gross margin is calculated from reported revenue and cost of sales. Both periods exclude depreciation and amortization from cost of sales.

Amtagvi drove commercial growth

U.S. Amtagvi revenue reached approximately $91 million and represented the primary source of quarterly sales. Total revenue also increased 39% from approximately $71 million in the first quarter of 2026, while Amtagvi revenue was 40% higher than in the fourth quarter of 2025. Global Proleukin contributed approximately $9 million, with differences in the product total reflecting rounded figures.

Iovance attributed Amtagvi demand to an expanded sales team, a new marketing campaign, wider adoption across authorized treatment centers, and earlier patient referrals. Unaided physician awareness has nearly tripled over the past year, according to the company.

The authorized treatment center network now includes more than 95 locations across the United States, Canada, and Australia. Iovance expects at least 110 centers to be active by the end of 2026, with community centers currently accounting for about one-third of the network. Manufacturing turnaround time is 31 days or less.

International expansion is progressing but remains dependent on authorization and reimbursement. Australia has approved Amtagvi, making it the product’s third global approval, while local centers are completing authorization and the company is discussing national reimbursement. The UK application was resubmitted in early July under expedited review for potential approval later in 2026, and potential Swiss approval is expected in the first half of 2027.

Higher volume and manufacturing efficiency narrowed losses

The improvement in profitability was not driven by revenue alone. Cost of sales declined to $43.6 million from $48.9 million even as revenue increased by more than $39 million. That lifted calculated gross profit to approximately $55.7 million from $11.1 million and raised gross margin to 56%.

Management attributed the margin improvement to higher Amtagvi volume, cost optimization, and maturing internal manufacturing efficiencies. R&D expense also declined by approximately one-quarter year over year, more than offsetting a modest increase in SG&A expense. Together, these changes reduced the operating loss by approximately $61.9 million.

The EPS comparison also reflects a larger share base. Weighted-average shares increased to 450.2 million from 334.5 million, so the smaller per-share loss resulted from both a lower net loss and a higher denominator.

At June 30, Iovance held $297.7 million of cash, cash equivalents, and investments, plus $6.0 million of restricted cash. The resulting cash position of approximately $304 million is expected by the company to fund operations into the second half of 2028. No quarterly operating or free cash flow figure was included in the release.

Clinical and regulatory milestones

The IOV-LUN-202 pivotal cohorts in previously treated metastatic non-squamous non-small-cell lung cancer are nearly fully enrolled. Program updates are expected in the fourth quarter of 2026, and Iovance plans a supplemental Biologics License Application submission in 2027.

The registrational SARATOGA trial in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma is underway. The FDA granted Fast Track Designation after an objective response rate of 50% was observed in the first six evaluable patients. Because that result comes from a small, early dataset, subsequent trial results will be important in assessing whether the response rate is sustained.

The Phase 3 TILVANCE-301 study continues enrolling frontline advanced melanoma patients, while the company is engaging with the FDA regarding a potential expedited pathway for metastatic serous endometrial cancer.

Management view

Management said second-quarter sales and current demand trends prompted a review of the existing 2026 revenue guidance of $350 million to $370 million. The company has not yet issued a revised range and plans to provide an update during the third quarter. It also expects gross margin improvement to continue, excluding occasional one-time items.

Risks investors should watch

• Revenue concentration: U.S. Amtagvi generated approximately $91 million of the company’s $99.3 million in quarterly revenue, leaving overall performance closely tied to adoption of one product in one primary market.
• Continued operating losses: Despite substantial improvement, Iovance still reported a $51.9 million operating loss and a $47.3 million net loss. Its projected cash runway depends on future spending, commercial performance, and development costs.
• Commercial execution: Growth depends on expanding and activating treatment centers, maintaining manufacturing efficiency, shortening institutional workflows, and securing reimbursement in new markets.
• Clinical and regulatory uncertainty: Several expansion opportunities rely on preliminary data, ongoing enrollment, future regulatory discussions, and planned submissions. Early results, including the sarcoma data from six evaluable patients, may not be replicated in larger studies.
• Share-base expansion: The weighted-average share count increased approximately 35% year over year, affecting how improvements in company-level losses translate to per-share results.

Summary

Iovance’s second-quarter 2026 results showed that rising Amtagvi volume and manufacturing efficiencies are improving the economics of its commercial business. Revenue increased 66%, gross margin reached 56%, and lower cost of sales and R&D spending substantially narrowed operating and net losses. The next major financial checkpoint is the company’s third-quarter update to its 2026 revenue outlook, while Amtagvi adoption, international reimbursement, margin progression, and upcoming clinical milestones remain the main operating indicators to monitor.